Emmy Boerrigter
Overview
Explore the profile of Emmy Boerrigter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Op t Hoog C, Rieborn A, Moes D, Hendrikx J, van der Heijden M, Franken M, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):36.
PMID: 39998586
Aim: Enfortumab vedotin is an antibody-drug conjugate (ADC) that has been approved for locally advanced or metastatic urothelial cancer, as monotherapy and in combination with pembrolizumab, and has shown significant...
2.
Op t Hoog C, Bosman S, Boerrigter E, Mehra N, van Oort I, van Erp N, et al.
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241305084.
PMID: 39687053
Background: The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI...
3.
Op t Hoog C, Mehra N, Maliepaard M, Bol K, Gelderblom H, Sonke G, et al.
Lancet Oncol
. 2024 Aug;
25(8):e340-e351.
PMID: 39089312
Historically, dose selection of anticancer drugs has mainly been based on establishing the maximum tolerated dose in phase 1 clinical trials with a traditional 3 plus 3 design. In the...
4.
Boerrigter E, Smolders E
Br J Clin Pharmacol
. 2024 Jun;
90(8):1880-1883.
PMID: 38880972
No abstract available.
5.
Boerrigter E, Overbeek J, Benoist G, Somford D, Hamberg P, Tol J, et al.
Eur Urol Oncol
. 2024 Mar;
7(6):1376-1383.
PMID: 38485614
Background And Objective: Enzalutamide is a potent androgen receptor signalling inhibitor, effectively used for the treatment of different stages of prostate cancer. Side effects occur frequently at the registered dose,...
6.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
7.
Otten L, Piet B, van den Haak D, Schouten R, Schuurbiers M, Badrising S, et al.
Clin Pharmacokinet
. 2023 Oct;
62(12):1749-1754.
PMID: 37856040
Introduction: Immune checkpoint inhibitors improved survival of advanced stage non-small cell lung cancer patients, but the overall response rate remains low. A biomarker that identifies non-responders would be helpful to...
8.
Podgorsek E, Mehra N, van Oort I, Somford D, Boerrigter E, van Erp N
Clin Pharmacokinet
. 2023 Jul;
62(8):1049-1061.
PMID: 37458966
Darolutamide is a next-generation androgen receptor signaling inhibitor (ARSI) currently approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC). Studies suggest that...
9.
Giraud E, de Lijster B, Krens S, Desar I, Boerrigter E, van Erp N
Lancet Oncol
. 2023 Jun;
24(6):e229.
PMID: 37269847
No abstract available.
10.
Tolmeijer S, Boerrigter E, Sumiyoshi T, Kwan E, Ng S, Annala M, et al.
Clin Cancer Res
. 2023 Mar;
29(15):2835-2844.
PMID: 36996325
Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is common. Early identification of resistance will improve management strategies....